Sangamo Therapeutics Company Profile (NASDAQ:SGMO)

About Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

Industry, Sector and Symbol:

Sector: Medical
Industry: Bio Therapeutic Drugs
Sub-Industry: Biotechnology
Symbol: NASDAQ:SGMO
CUSIP: 80067710
Web: www.sangamo.com

Capitalization:

Market Cap: $1.12457 billion
Outstanding Shares: 83,610,000

Average Prices:

50 Day Moving Avg: $14.54
200 Day Moving Avg: $9.48
52 Week Range: $2.65 - $17.06

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -16.81
P/E Growth: 0.00

Sales & Book Value:

Annual Revenue: $23.42 million
Price / Sales: 48.02
Book Value: $2.32 per share
Price / Book: 5.80

Profitability:

EBITDA: ($57,470,000.00)
Net Margins: -246.39%
Return on Equity: -38.49%
Return on Assets: -30.67%

Debt:

Debt-to-Equity Ratio: 0.02%
Current Ratio: 6.14%
Quick Ratio: 6.14%

Misc:

Average Volume: 1.64 million shs.
Beta: 3.14
Short Ratio: 8.11

Frequently Asked Questions for Sangamo Therapeutics (NASDAQ:SGMO)

What is Sangamo Therapeutics' stock symbol?

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) issued its earnings results on Wednesday, August, 9th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.06. The business had revenue of $8.30 million for the quarter, compared to analyst estimates of $5.82 million. Sangamo Therapeutics had a negative return on equity of 38.49% and a negative net margin of 246.39%. The business's quarterly revenue was up 124.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.38) EPS. View Sangamo Therapeutics' Earnings History.

When will Sangamo Therapeutics make its next earnings announcement?

Sangamo Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Sangamo Therapeutics.

Where is Sangamo Therapeutics' stock going? Where will Sangamo Therapeutics' stock price be in 2017?

5 equities research analysts have issued 12-month price objectives for Sangamo Therapeutics' shares. Their predictions range from $4.00 to $30.00. On average, they anticipate Sangamo Therapeutics' stock price to reach $15.00 in the next year. View Analyst Ratings for Sangamo Therapeutics.

What are analysts saying about Sangamo Therapeutics stock?

Here are some recent quotes from research analysts about Sangamo Therapeutics stock:

1. According to Zacks Investment Research, "Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States. " (8/18/2017)
2. Cowen and Company analysts commented, "We hosted a group lunch meeting with SGMO management this week." (3/22/2017)
3. Piper Jaffray Companies analysts commented, "Today Sangamo reported 4Q16 financial results, ending the quarter with ~$143M in cash. With updated 2017 guidance on operating expenses incorporated into our model, we expect this cash runway can fund the company through 1H18. This period should include the first safety and biomarker data from early cohorts of patients treated in its open, or soon-to-be opened, clinical trials for Hem A, Hem B, MPS I, and MPS II. Although we expect these early results in late'17/early '18 to focus primarily on safety and pharmacodynamic signals of activity and thus not yet be definitive for informing pivotal programs, we nonetheless believe this progress to be critical for evaluating turn-around efforts and establishing a new era of clinical achievement for Sangamo. That said, in advance of enrollment updates and increased visibility on clinical progress for Sangamo's broadening but early pipeline, we remain on the sidelines with a Neutral rating." (2/28/2017)

Who are some of Sangamo Therapeutics' key competitors?

Some companies that are related to Sangamo Therapeutics include Prothena Corporation PLC (PRTA), Ultragenyx Pharmaceutical (RARE), China Biologic Products (CBPO), Array BioPharma (ARRY), Insmed (INSM), Intercept Pharmaceuticals (ICPT), NovoCure Limited (NVCR), Acceleron Pharma (XLRN), Radius Health (RDUS), AnaptysBio (ANAB), Five Prime Therapeutics (FPRX), MyoKardia (MYOK), Clinigen Group PLC (CLIN), Ascendis Pharma A/S (ASND), Acorda Therapeutics (ACOR), Dynavax Technologies Corporation (DVAX), Dermira (DERM) and Lexicon Pharmaceuticals (LXRX).

Who are Sangamo Therapeutics' key executives?

Sangamo Therapeutics' management team includes the folowing people:

Alexander D. Macrae Ph.D., President, Chief Executive Officer, Director
Kathy Y. Yi, Chief Financial Officer, Senior Vice President
Edward R. Conner M.D., Senior Vice President and Chief Medical Officer
Curt Herberts III, Senior Vice President and Chief Business Officer
Dale G. Ando M.D., Vice President - Therapeutic Development, Chief Medical Officer
Roger Jeffs Ph.D., Director
Joseph S. Zakrzewski, Director
Robert F. Carey, Independent Director
Stephen G. Dilly M.D. Ph.D., Independent Director
Steven J. Mento Ph.D., Independent Director

How do I buy Sangamo Therapeutics stock?

Shares of Sangamo Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sangamo Therapeutics' stock price today?

One share of Sangamo Therapeutics stock can currently be purchased for approximately $13.45.

MarketBeat Community Rating for Sangamo Therapeutics (NASDAQ SGMO)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		193 (Vote Outperform)
Underperform Votes:		147 (Vote Underperform)
Total Votes:		340

MarketBeat's community ratings are surveys of what our community members think about Sangamo Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Sangamo Therapeutics (NASDAQ:SGMO) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	2 Hold Ratings, 3 Buy Ratings
Consensus Rating:	Buy (Score: 2.60)
Consensus Price Target:	$15.00 (11.52% upside)

Consensus Price Target History for Sangamo Therapeutics (NASDAQ:SGMO)

Analysts' Ratings History for Sangamo Therapeutics (NASDAQ:SGMO)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
10/13/2017	Jefferies Group LLC	Reiterated Rating	Buy	$18.00	N/A
9/5/2017	Wells Fargo & Company	Reiterated Rating	Outperform	$20.00 -> $30.00	Low
8/10/2017	Piper Jaffray Companies	Set Price Target	Hold	$8.00	High
5/16/2017	Wedbush	Reiterated Rating	Neutral	$6.00 -> $4.00	Medium
3/22/2017	Cowen and Company	Reiterated Rating	Buy		High
8/4/2016	Janney Montgomery Scott	Downgrade	Buy -> Neutral	$15.00 -> $8.00	N/A
2/10/2016	J P Morgan Chase & Co	Reiterated Rating	Overweight	$16.00	N/A

(Data available from 10/22/2015 forward)

Earnings History for Sangamo Therapeutics (NASDAQ:SGMO)

Earnings by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Earnings History by Quarter for Sangamo Therapeutics (NASDAQ SGMO)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
10/24/2017		($0.19)					N/A
8/9/2017	Q2 2017	($0.23)	($0.17)	$5.82 million	$8.30 million	View	Listen
5/10/2017	Q1 2017	($0.26)	($0.23)	$4.14 million	$3.40 million	View	N/A
2/28/2017	Q416	($0.26)	($0.14)	$3.91 million	$8.90 million	View	Listen
10/26/2016	Q316	($0.25)	($0.27)	$4.24 million	$2.82 million	View	Listen
8/3/2016	Q216	($0.24)	($0.38)	$5.38 million	$3.70 million	View	N/A
5/2/2016	Q116	($0.24)	($0.23)	$5.49 million	$3.94 million	View	N/A
2/9/2016	Q415	($0.21)	($0.20)	$9.86 million	$9.10 million	View	N/A
10/28/2015	Q315	($0.25)	($0.13)	$13.09 million	$8.57 million	View	Listen
8/5/2015	Q215	($0.13)	($0.17)	$14.72 million	$8.36 million	View	Listen
4/22/2015	Q115	($0.13)	($0.08)	$12.50 million	$13.50 million	View	Listen
2/10/2015	Q414	($0.09)	($0.06)	$14.50 million	$15.00 million	View	N/A
10/22/2014	Q314	($0.04)	($0.11)	$8.27 million	$12.40 million	View	Listen
7/23/2014	Q214	($0.14)	($0.10)	$7.84 million	$10.38 million	View	Listen
5/6/2014	Q114	($0.13)	($0.12)	$6.59 million	$8.10 million	View	Listen
2/11/2014	Q413	($0.10)	($0.13)	$8.90 million	$6.90 million	View	Listen
10/23/2013	Q313	($0.11)	($0.11)	$5.52 million	$5.70 million	View	N/A
7/24/2013	Q2 2013	($0.12)	($0.10)	$4.77 million	$6.90 million	View	N/A
5/8/2013	Q1 2013	($0.17)	($0.13)	$3.79 million	$4.60 million	View	N/A
2/6/2013	Q4 2012	($0.12)	($0.07)	$5.95 million	$8.93 million	View	N/A
10/24/2012	Q312	($0.14)	($0.11)	$3.80 million	$4.90 million	View	N/A
7/25/2012		($0.15)	($0.11)			View	N/A
5/2/2012		($0.16)	($0.14)			View	N/A
10/25/2011		($0.16)	($0.18)			View	N/A
7/27/2011		($0.16)	($0.20)			View	N/A
4/26/2011		($0.17)	($0.21)			View	N/A
2/2/2011		($0.19)	($0.18)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

2017 EPS Consensus Estimate: ($0.87)
2018 EPS Consensus Estimate: ($0.98)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	2	($0.25)	($0.23)	($0.24)
Q2 2017	2	($0.23)	($0.12)	($0.18)
Q3 2017	2	($0.22)	($0.21)	($0.22)
Q4 2017	2	($0.25)	($0.23)	($0.24)
Q1 2018	1	($0.25)	($0.25)	($0.25)
Q2 2018	1	($0.25)	($0.25)	($0.25)
Q3 2018	1	($0.24)	($0.24)	($0.24)
Q4 2018	1	($0.24)	($0.24)	($0.24)

(Data provided by Zacks Investment Research)

Dividend History for Sangamo Therapeutics (NASDAQ:SGMO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Sangamo Therapeutics (NASDAQ:SGMO)

Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 63.43%

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Insider Trades by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
10/2/2017	Curt A Herberts III	VP	Sell	15,000	$15.25	$228,750.00
9/20/2017	William R Ringo	Director	Sell	31,000	$14.37	$445,470.00
9/1/2017	Curt A Herberts III	VP	Sell	15,000	$15.00	$225,000.00
8/14/2017	Curt A Herberts III	VP	Sell	11,474	$10.44	$119,788.56
7/14/2017	Curt A Herberts III	VP	Sell	15,000	$10.00	$150,000.00
6/1/2017	Curt A. Herberts III	VP	Sell	2,000	$6.80	$13,600.00
5/12/2017	Curt A. Herberts III	VP	Sell	2,639	$8.02	$21,164.78
8/1/2015	Ra Capital Management, Llc	Major Shareholder	Sell	27,770	$12.82	$356,011.40
7/30/2015	Ra Capital Management, Llc	Major Shareholder	Sell	109,590	$12.42	$1,361,107.80
7/29/2015	Ra Capital Management, Llc	Major Shareholder	Sell	1,407	$12.41	$17,460.87
7/28/2015	Ra Capital Management, Llc	Major Shareholder	Sell	60,081	$12.11	$727,580.91
7/25/2015	Ra Capital Management, Llc	Major Shareholder	Sell	47,429	$12.31	$583,850.99
7/24/2015	Ra Capital Management, Llc	Major Shareholder	Sell	124,050	$12.28	$1,523,334.00
7/17/2015	Ra Capital Management, Llc	Major Shareholder	Buy	37,215	$12.26	$456,255.90
7/15/2015	Edward O Lanphier II	CEO	Sell	25,000	$10.43	$260,750.00
7/13/2015	Henry Ward Wolff	CFO	Sell	12,000	$10.00	$120,000.00
7/1/2015	Ra Capital Management, Llc	Major Shareholder	Sell	82,700	$16.01	$1,324,027.00
6/16/2015	Ra Capital Management, Llc	Major Shareholder	Sell	250,500	$16.55	$4,145,775.00
6/9/2015	Ra Capital Management, Llc	Major Shareholder	Sell	83,500	$15.50	$1,294,250.00
6/6/2015	Ra Capital Management, Llc	Major Shareholder	Sell	135,101	$14.29	$1,930,593.29
6/5/2015	Dale G Ando	CMO	Sell	15,000	$12.29	$184,350.00
6/5/2015	Ra Capital Management, Llc	Major Shareholder	Sell	115,102	$14.13	$1,626,391.26
6/4/2015	Ra Capital Management, Llc	Major Shareholder	Sell	70,640	$13.10	$925,384.00
6/3/2015	Ra Capital Management, Llc	Major Shareholder	Sell	76,833	$12.86	$988,072.38
6/3/2015	William R Ringo	Director	Sell	2,200	$12.44	$27,368.00
6/1/2015	Philip D Gregory	SVP	Sell	15,000	$12.39	$185,850.00
5/30/2015	Ra Capital Management, Llc	Major Shareholder	Sell	65,884	$13.40	$882,845.60
5/29/2015	Ra Capital Management, Llc	Major Shareholder	Sell	155,675	$13.53	$2,106,282.75
5/28/2015	Ra Capital Management, Llc	Major Shareholder	Sell	148,689	$13.43	$1,996,893.27
5/27/2015	Ra Capital Management, Llc	Major Shareholder	Sell	263,437	$13.55	$3,569,571.35
5/23/2015	Ra Capital Management, Llc	Major Shareholder	Sell	51,597	$13.27	$684,692.19
5/22/2015	Ra Capital Management, Llc	Major Shareholder	Sell	56,396	$13.56	$764,729.76
5/13/2015	Ra Capital Management, Llc	Major Shareholder	Sell	56,060	$13.12	$735,507.20
5/12/2015	Ra Capital Management, Llc	Major Shareholder	Sell	29,659	$13.03	$386,456.77
5/8/2015	Ra Capital Management, Llc	Major Shareholder	Sell	83,300	$12.40	$1,032,920.00
5/7/2015	Ra Capital Management, Llc	Major Shareholder	Buy	35,736	$12.09	$432,048.24
5/5/2015	Dale G Ando	CMO	Sell	15,000	$12.29	$184,350.00
5/4/2015	William R Ringo	Director	Sell	3,000	$12.98	$38,940.00
4/30/2015	Ra Capital Management, Llc	Major Shareholder	Buy	124,500	$13.45	$1,674,525.00
4/28/2015	Ra Capital Management, Llc	Major Shareholder	Buy	74,844	$13.29	$994,676.76
4/25/2015	Ra Capital Management, Llc	Major Shareholder	Buy	166,000	$13.63	$2,262,580.00
4/22/2015	Ra Capital Management, Llc	Major Shareholder	Sell	352,750	$14.86	$5,241,865.00
4/17/2015	Ra Capital Management, Llc	Major Shareholder	Buy	41,500	$14.02	$581,830.00
4/16/2015	Ra Capital Management, Llc	Major Shareholder	Sell	21,829	$14.09	$307,570.61
4/15/2015	Edward O Lanphier II	CEO	Sell	25,000	$15.33	$383,250.00
4/15/2015	Ra Capital Management, Llc	Major Shareholder	Buy	21,829	$13.16	$287,269.64
4/14/2015	Ra Capital Management, Llc	Major Shareholder	Sell	3,055	$14.78	$45,152.90
4/11/2015	Ra Capital Management, Llc	Major Shareholder	Buy	116,992	$14.48	$1,694,044.16
4/10/2015	Henry Ward Wolff	CFO	Sell	12,000	$15.31	$183,720.00
4/10/2015	Ra Capital Management, Llc	Major Shareholder	Buy	83,000	$14.91	$1,237,530.00
4/9/2015	Ra Capital Management, Llc	Major Shareholder	Sell	69,856	$16.27	$1,136,557.12
4/8/2015	Ra Capital Management, Llc	Major Shareholder	Buy	121,876	$15.49	$1,887,859.24
4/7/2015	Ra Capital Management, Llc	Major Shareholder	Buy	33,667	$15.42	$519,145.14
4/6/2015	Dale G Ando	CMO	Sell	15,000	$14.94	$224,100.00
4/6/2015	William R Ringo	Director	Sell	2,200	$14.95	$32,890.00
4/4/2015	Ra Capital Management, Llc	Major Shareholder	Buy	179,031	$15.38	$2,753,496.78
4/3/2015	Ra Capital Management, Llc	Major Shareholder	Buy	195,126	$16.61	$3,241,042.86
4/1/2015	Philip D Gregory	SVP	Sell	15,000	$15.15	$227,250.00
4/1/2015	Ra Capital Management, Llc	Major Shareholder	Sell	250,000	$18.01	$4,502,500.00
3/28/2015	Ra Capital Management, Llc	Major Shareholder	Buy	84,000	$17.10	$1,436,400.00
3/27/2015	Ra Capital Management, Llc	Major Shareholder	Buy	256,187	$17.65	$4,521,700.55
3/26/2015	Ra Capital Management, Llc	Major Shareholder	Buy	210,013	$18.14	$3,809,635.82
3/25/2015	Ra Capital Management, Llc	Major Shareholder	Buy	84,000	$19.42	$1,631,280.00
3/21/2015	Ra Capital Management, Llc	Major Shareholder	Buy	101,808	$21.22	$2,160,365.76
3/19/2015	Henry Ward Wolff	CFO	Sell	10,000	$18.00	$180,000.00
3/19/2015	Ra Capital Management, Llc	Major Shareholder	Sell	17,808	$24.28	$432,378.24
3/18/2015	Ra Capital Management, Llc	Major Shareholder	Sell	84,000	$23.74	$1,994,160.00
3/17/2015	Ra Capital Management, Llc	Major Shareholder	Buy	52,161	$23.02	$1,200,746.22
3/16/2015	Edward O Lanphier II	CEO	Sell	25,000	$17.29	$432,250.00
3/13/2015	Ra Capital Management, Llc	Major Shareholder	Buy	71,319	$22.76	$1,623,220.44
3/12/2015	Ra Capital Management, Llc	Major Shareholder	Sell	123,480	$23.40	$2,889,432.00
3/10/2015	Ra Capital Management, Llc	Major Shareholder	Buy	12,522	$22.30	$279,240.60
3/7/2015	Ra Capital Management, Llc	Major Shareholder	Buy	258,377	$22.25	$5,748,888.25
3/6/2015	Ra Capital Management, Llc	Major Shareholder	Sell	61,483	$24.10	$1,481,740.30
3/3/2015	Ra Capital Management, Llc	Major Shareholder	Sell	84,000	$18.21	$1,529,640.00
3/3/2015	William R Ringo	Director	Sell	2,200	$17.21	$37,862.00
3/2/2015	Philip D Gregory	SVP	Sell	15,000	$17.26	$258,900.00
2/28/2015	Ra Capital Management, Llc	Major Shareholder	Buy	42,000	$18.10	$760,200.00
2/27/2015	Ra Capital Management, Llc	Major Shareholder	Sell	32,196	$19.37	$623,636.52
2/26/2015	Ra Capital Management, Llc	Major Shareholder	Buy	74,194	$19.57	$1,451,976.58
2/20/2015	Ra Capital Management, Llc	Major Shareholder	Sell	35,319	$18.40	$649,869.60
2/19/2015	Ra Capital Management, Llc	Major Shareholder	Sell	6,720	$18.51	$124,387.20
2/18/2015	Ra Capital Management, Llc	Major Shareholder	Sell	11,172	$18.11	$202,324.92
2/14/2015	Ra Capital Management, Llc	Major Shareholder	Sell	15,380	$18.61	$286,221.80
2/13/2015	Ra Capital Management, Llc	Major Shareholder	Sell	15,409	$18.46	$284,450.14
2/12/2015	Ra Capital Management, Llc	Major Shareholder	Buy	42,000	$18.04	$757,680.00
2/12/2015	Saira Ramasastry	Director	Sell	10,000	$15.00	$150,000.00
2/11/2015	Ra Capital Management, Llc	Major Shareholder	Buy	42,000	$19.65	$825,300.00
2/7/2015	Ra Capital Management, Llc	Major Shareholder	Sell	34,688	$18.52	$642,421.76
2/6/2015	Ra Capital Management, Llc	Major Shareholder	Sell	7,312	$18.42	$134,687.04
2/5/2015	Dale G Ando	CMO	Sell	15,000	$12.93	$193,950.00
2/5/2015	Ra Capital Management, Llc	Major Shareholder	Buy	42,000	$18.23	$765,660.00
2/3/2015	William R Ringo	Director	Sell	2,200	$12.70	$27,940.00
2/2/2015	Philip D Gregory	SVP	Sell	15,000	$12.86	$192,900.00
1/16/2015	Edward O Lanphier II	CEO	Sell	25,000	$14.22	$355,500.00
1/12/2015	Henry Ward Wolff	CFO	Sell	12,000	$15.87	$190,440.00
1/5/2015	Dale G Ando	CMO	Sell	15,000	$15.19	$227,850.00
1/5/2015	William R Ringo	Director	Sell	2,200	$15.20	$33,440.00
12/15/2014	Edward O Lanphier II	CEO	Sell	25,000	$15.40	$385,000.00
12/15/2014	John William Larson	Director	Sell	10,000	$16.28	$162,800.00
12/9/2014	John William Larson	Director	Sell	10,000	$12.00	$120,000.00
12/1/2014	Philip D Gregory	SVP	Sell	15,000	$11.68	$175,200.00
11/17/2014	Edward O Lanphier II	CEO	Sell	25,000	$11.23	$280,750.00
11/12/2014	John William Larson	Director	Sell	10,000	$12.00	$120,000.00
11/3/2014	Philip D Gregory	SVP	Sell	15,000	$11.91	$178,650.00
10/28/2014	John William Larson	Director	Sell	10,000	$12.02	$120,200.00
10/10/2014	Henry Ward Wolff	CFO	Sell	2,000	$10.10	$20,200.00
10/6/2014	Dale G Ando	CMO	Sell	15,000	$10.72	$160,800.00
10/1/2014	Philip D Gregory	SVP	Sell	15,000	$10.80	$162,000.00
9/15/2014	Edward O Lanphier II	CEO	Sell	25,000	$12.14	$303,500.00
9/10/2014	Henry Ward Wolff	CFO	Sell	2,000	$12.31	$24,620.00
9/5/2014	Dale G Ando	CMO	Sell	15,000	$12.20	$183,000.00
9/4/2014	John William Larson	Director	Sell	10,000	$12.81	$128,100.00
8/15/2014	Edward O Lanphier II	CEO	Sell	25,000	$13.95	$348,750.00
8/11/2014	Henry Ward Wolff	CFO	Sell	10,000	$14.17	$141,700.00
8/5/2014	Dale G Ando	CMO	Sell	15,000	$12.99	$194,850.00
8/4/2014	John William Larson	Director	Sell	10,000	$12.56	$125,600.00
8/1/2014	Philip D Gregory	SVP	Sell	15,000	$12.54	$188,100.00
7/18/2014	Edward O Lanphier II	CEO	Sell	25,000	$12.16	$304,000.00
7/10/2014	Henry Ward Wolff	CFO	Sell	15,000	$13.26	$198,900.00
7/1/2014	Philip D Gregory	SVP	Sell	15,000	$15.66	$234,900.00
6/23/2014	Saira Ramasastry	Director	Sell	5,550	$15.53	$86,191.50
6/16/2014	Edward O Lanphier II	CEO	Sell	25,000	$16.41	$410,250.00
6/10/2014	Henry Ward Wolff	CFO	Sell	15,000	$15.62	$234,300.00
6/2/2014	Philip D Gregory	SVP	Sell	15,000	$12.85	$192,750.00
5/15/2014	Edward Lanphier II	CEO	Sell	25,000	$13.14	$328,500.00
5/1/2014	Philip Gregory	SVP	Sell	15,000	$13.68	$205,200.00
4/28/2014	Dale Ando	CMO	Sell	15,000	$13.64	$204,600.00
4/28/2014	John William Larson	Director	Sell	10,000	$13.48	$134,800.00
4/15/2014	Edward Lanphier II	CEO	Sell	25,000	$14.20	$355,000.00
4/10/2014	Henry Ward Wolff	CFO	Sell	15,000	$15.72	$235,800.00
3/26/2014	Dale Ando	CMO	Sell	15,000	$18.65	$279,750.00
3/21/2014	Philip Gregory	Insider	Sell	15,000	$22.38	$335,700.00
3/17/2014	Edward Lanphier II	CEO	Sell	50,000	$23.22	$1,161,000.00
3/17/2014	Saira Ramasastry	Director	Sell	10,000	$23.26	$232,600.00
3/14/2014	Steven Mento	Director	Sell	6,103	$22.77	$138,965.31
2/18/2014	Edward Lanphier II	CEO	Sell	50,000	$18.09	$904,500.00
1/27/2014	Dale Ando	CMO	Sell	15,000	$18.58	$278,700.00
1/10/2014	Henry Ward Wolff	CFO	Sell	10,000	$18.69	$186,900.00
1/2/2014	Philip Gregory	VP	Sell	15,000	$13.56	$203,400.00
12/26/2013	Dale Ando	CMO	Sell	15,000	$14.37	$215,550.00
11/15/2013	Edward Lanphier II	CEO	Sell	25,000	$10.11	$252,750.00
11/5/2013	Philip D Gregory	VP	Sell	15,000	$9.60	$144,000.00
10/28/2013	Dale G Ando	CMO	Sell	15,000	$10.39	$155,850.00
10/21/2013	Paul B Cleveland	Director	Sell	10,000	$10.93	$109,300.00
10/15/2013	Edward O Lanphier II	CEO	Sell	25,000	$11.32	$283,000.00
10/10/2013	Henry Ward Wolff	CFO	Sell	10,000	$11.28	$112,800.00
10/1/2013	Philip D Gregory	VP	Sell	15,000	$10.54	$158,100.00
9/16/2013	Edward Lanphier II	CEO	Sell	25,000	$11.29	$282,250.00
9/10/2013	Henry Ward Wolff	CFO	Sell	10,000	$10.86	$108,600.00
9/3/2013	Paul Cleveland	Director	Sell	7,278	$10.30	$74,963.40
9/3/2013	Philip Gregory	VP	Sell	15,000	$10.33	$154,950.00
8/26/2013	Dale Ando	CMO	Sell	15,000	$10.04	$150,600.00
8/15/2013	Edward Lanphier II	CEO	Sell	25,000	$10.12	$253,000.00
8/13/2013	Henry Ward Wolff	CFO	Sell	10,000	$10.00	$100,000.00
8/1/2013	Philip Gregory	VP	Sell	15,000	$9.89	$148,350.00
7/29/2013	Philip D Gregory	VP	Sell	15,000	$10.04	$150,600.00
7/26/2013	Dale G Ando	CMO	Sell	15,000	$10.09	$151,350.00
7/17/2013	Edward O Lanphier II	CEO	Sell	25,000	$10.00	$250,000.00
7/17/2013	Henry Ward Wolff	CFO	Sell	10,000	$10.00	$100,000.00
7/15/2013	Paul B Cleveland	Director	Sell	8,000	$9.59	$76,720.00
6/3/2013	Philip D Gregory	VP	Sell	3,000	$7.88	$23,640.00
5/28/2013	Dale G Ando	CMO	Sell	15,000	$8.32	$124,800.00
4/10/2013	Henry Ward Wolff	CFO	Sell	10,000	$10.00	$100,000.00
12/26/2012	Dale G Ando	CMO	Sell	17,000	$5.92	$100,640.00
12/3/2012	John William Larson	Director	Sell	15,000	$5.64	$84,600.00
9/5/2012	Dale G Ando	CMO	Sell	15,000	$5.60	$84,000.00
9/4/2012	John William Larson	Director	Sell	15,000	$5.30	$79,500.00

(Data available from 1/1/2013 forward)

Headline Trends for Sangamo Therapeutics (NASDAQ:SGMO) Latest Headlines for Sangamo Therapeutics (NASDAQ:SGMO)

Source:

Loading headlines, please wait.

Sangamo Therapeutics (SGMO) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Sangamo Therapeutics Company Profile (NASDAQ:SGMO)

About Sangamo Therapeutics (NASDAQ:SGMO)

What is Sangamo Therapeutics' stock symbol?

How were Sangamo Therapeutics' earnings last quarter?

When will Sangamo Therapeutics make its next earnings announcement?

Where is Sangamo Therapeutics' stock going? Where will Sangamo Therapeutics' stock price be in 2017?

What are analysts saying about Sangamo Therapeutics stock?

Who are some of Sangamo Therapeutics' key competitors?

Who are Sangamo Therapeutics' key executives?

How do I buy Sangamo Therapeutics stock?

What is Sangamo Therapeutics' stock price today?

Analyst Ratings

Earnings

Estimates

Dividends

Insider Trades

Headlines

Social

Chart